Merck's IMPROVE-IT: FDA Panel Review Has Implications Beyond Zetia, Vytorin
This article was originally published in The Pink Sheet Daily
Executive Summary
Whether FDA agrees that results from ezetimibe cardiovascular outcomes study confirm the LDL hypothesis for non-statin drugs is of keen interest to sponsors of PSCK9 inhibitors and other novel lipid-lowering agents.
You may also be interested in...
PCSK9 Inhibitors May Feel Effects Of FDA Judgment On IMPROVE-IT
Agency's decision on cardiovascular risk reduction claims for Merck's Zetia and Vytorin may serve as a regulatory barometer for the magnitude and robustness of effect that will be expected in outcomes studies for other LDL-C-lowering agents.
Merck's IMPROVE-IT Study: Will Missing Data, Subgroups Hinder Zetia CV Claim?
FDA asks advisory committee to weigh impact of missing follow-up and 'notable differences' in subgroup treatment effects on company's request for broad cardiovascular benefit claim for Zetia and Vytorin.
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming FDA advisory committee meetings and a summary of topics covered.